BioXcel Therapeutics, Inc. Restructuring Charges
BioXcel Therapeutics, Inc. (BTAI) reported Restructuring Charges of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-05-15
- BioXcel Therapeutics, Inc. restructuring charges for the quarter ending 2026-03-31 was $0.00.
- BioXcel Therapeutics, Inc. restructuring charges for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- BioXcel Therapeutics, Inc. restructuring charges for the quarter ending 2025-09-30 was $194.00K, a 87.51% decline year-over-year.
- BioXcel Therapeutics, Inc. restructuring charges for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- BioXcel Therapeutics, Inc. restructuring charges for fiscal 2025 was $194.00K, a 92.05% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. restructuring charges for fiscal 2024 was $2.44M, a 41.36% decline from fiscal 2023.
- BioXcel Therapeutics, Inc. restructuring charges for fiscal 2023 was $4.16M.
| Period end | Restructuring Charges | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-05-15 | $194.00K derived: sum of 3 quarters · filed 2026-05-15 | $194.00K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $194.00K derived: sum of 2 quarters · filed 2026-03-27 | $194.00K derived: sum of 3 quarters · filed 2026-03-27 | $194.00K 10-K · filed 2026-03-27 | |
| 2025-09-30 | $194.00K 10-Q · filed 2025-11-12 | $194.00K derived: sum of 2 quarters · filed 2025-11-12 | $194.00K 10-Q · filed 2025-11-12 | $227.00K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | $33.00K derived: sum of 3 quarters · filed 2026-05-15 | $1.59M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-15 | $33.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.59M derived: sum of 3 quarters · filed 2026-05-15 | $2.44M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $33.00K 10-K · filed 2025-03-28 | $1.59M derived: sum of 2 quarters · filed 2025-11-12 | $2.44M derived: sum of 3 quarters · filed 2025-11-12 | $2.44M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $1.55M 10-Q · filed 2025-11-12 | $2.41M derived: sum of 2 quarters · filed 2025-11-12 | $2.41M 10-Q · filed 2025-11-12 | ||
| 2024-09-17 | $1.55M 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | $856.00K 10-Q · filed 2025-08-12 | $856.00K 10-Q · filed 2025-08-12 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $4.16M derived: sum of 2 quarters · filed 2025-03-28 | $4.16M 10-K · filed 2025-03-28 | ||
| 2023-09-30 | $4.16M 10-Q · filed 2024-11-14 | $4.16M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |